Autolus Therapeutics plc

Autolus Therapeutics plcverified

AUTL

Price:

$3.92

Market Cap:

$1.04B

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; a...[Read more]

Industry

Biotechnology

IPO Date

2018-06-22

Stock Exchange

NASDAQ

Ticker

AUTL

The PE Ratio as of May 2024 (TTM) for Autolus Therapeutics plc (AUTL) is -3.24

According to Autolus Therapeutics plc’s latest financial reports and current stock price. The company's current PE Ratio is -3.24. This represents a change of -8.08% compared to the average of -3.52 of the last 4 quarters.

Autolus Therapeutics plc (AUTL) Historical PE Ratio (quarterly & annually)

How has AUTL PE Ratio performed in the past?

The mean historical PE Ratio of Autolus Therapeutics plc over the last ten years is -11.63. The current -3.24 PE Ratio has changed 2.69% with respect to the historical average. Over the past ten years (40 quarters), AUTL's PE Ratio was at its highest in in the March 2018 quarter at 0. The PE Ratio was at its lowest in in the December 2018 quarter at -15.61.

Quarterly (TTM)
Annual

Average

-11.63

Median

-4.98

Minimum

-31.08

Maximum

-1.21

Autolus Therapeutics plc (AUTL) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Autolus Therapeutics plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 343.30%

Maximum Annual PE Ratio = -1.21

Minimum Annual Increase = -85.23%

Minimum Annual PE Ratio = -31.08

Quarterly (TTM)
Annual
YearPE RatioChange
2023-5.38343.30%
2022-1.21-53.94%
2021-2.63-18.84%
2020-3.24-29.33%
2019-4.59-85.23%
2018-31.0877.91%
2017-17.47-36.38%

Autolus Therapeutics plc (AUTL) Average PE Ratio

How has AUTL PE Ratio performed in the past?

The current PE Ratio of Autolus Therapeutics plc (AUTL) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-3.07

5-year avg

-3.41

10-year avg

-11.63

Autolus Therapeutics plc (AUTL) PE Ratio vs. Peers

How is AUTL’s PE Ratio compared to its peers?

Autolus Therapeutics plc’s PE Ratio is greater than Cullinan Oncology, Inc. (-7.84), less than Bolt Biotherapeutics, Inc. (-0.48), greater than Day One Biopharmaceuticals, Inc. (-5.71), less than Lyra Therapeutics, Inc. (-0.30), greater than Acumen Pharmaceuticals, Inc. (-3.64), less than X4 Pharmaceuticals, Inc. (-1.40), greater than Inozyme Pharma, Inc. (-3.66), greater than VectivBio Holding AG (-7.94), greater than Terns Pharmaceuticals, Inc. (-4.90), less than Amylyx Pharmaceuticals, Inc. (-1.65), less than Ikena Oncology, Inc. (-0.92), greater than Anebulo Pharmaceuticals, Inc. (-5.87), greater than Celcuity Inc. (-7.16), greater than MediciNova, Inc. (-7.82), less than Rezolute, Inc. (-3.11), greater than Mirati Therapeutics, Inc. (-5.32), greater than Apellis Pharmaceuticals, Inc. (-11.97),

Build a custom stock screener for Autolus Therapeutics plc (AUTL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Autolus Therapeutics plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Autolus Therapeutics plc (AUTL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Autolus Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Autolus Therapeutics plc's PE Ratio?

How is the PE Ratio calculated for Autolus Therapeutics plc (AUTL)?

What is the highest PE Ratio for Autolus Therapeutics plc (AUTL)?

What is the 3-year average PE Ratio for Autolus Therapeutics plc (AUTL)?

What is the 5-year average PE Ratio for Autolus Therapeutics plc (AUTL)?

How does the current PE Ratio for Autolus Therapeutics plc (AUTL) compare to its historical average?